Focused On-demand Library for Vang-like protein 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9ULK5

UPID:

VANG2_HUMAN

Alternative names:

Loop-tail protein 1 homolog; Strabismus 1; Van Gogh-like protein 2

Alternative UPACC:

Q9ULK5; D3DVE9; Q5T212

Background:

Vang-like protein 2, also known as Loop-tail protein 1 homolog, Strabismus 1, and Van Gogh-like protein 2, plays a pivotal role in early morphogenesis and patterning of axial midline structures and neural plate development. It is crucial for the regulation of planar cell polarity, especially in the orientation of stereociliary bundles in the cochlea, and is involved in myocardializing cells' polarization and movement in the outflow tract through RHOA signaling.

Therapeutic significance:

Given its involvement in neural tube defects, a condition stemming from defective neural tube closure linked to both genetic and environmental factors, Vang-like protein 2 represents a significant target for therapeutic intervention. Understanding the role of Vang-like protein 2 could open doors to potential therapeutic strategies.